- Molecular NameButalbital
- SynonymAllylbarbital; Butalbital M (OH)
- Weight224.26
- Drugbank_IDDB00241
- ACS_NO77-26-9
- Show 3D model
- LogP (experiment)1.429
- LogP (predicted, AB/LogP v2.0)1.59
- pka7.6
- LogD (pH=7, predicted)1.54
- Solubility (experiment)1.7 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-2.31
- LogSw (predicted, AB/LogsW2.0)1.17
- Sw (mg/ml) (predicted, ACD/Labs)0.95
- No.of HBond Donors2
- No.of HBond Acceptors5
- No.of Rotatable Bonds4
- TPSA75.27
- StatusFDA approved
- AdministrationN/A
- PharmacologyButalbital is often combined with other medications, such as paracetamol (acetaminophen) or aspirin, and is commonly prescribed for the treatment of pain and headache. The various formulations combined with codeine are FDA approved for the treatment of tension headaches.
- Absorption_valueN/A
- Absorption (description)Absorbed after oral administration.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding45.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- Metabollsmhepatic
- Half life30~40 h (Derived from urinary excretion data)
- ExcretionAbout 5% of a dose is excreted in the urine as unchanged drug in 96 h and 20 to 60% as 5-(2,3-dihydroxypropyl)-5-isobutylbarbituric acid.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityPlasma concentrations of 10 to 25 mg/L are usually associated with toxic effects. The following concentrations were reported in one fatality attributed to butalbital overdose: blood 26 mg/L, liver 50 μg/g. [R. C. Baselt and R. H. Cravey,J. Anal. Toxicol.,1977, 1, 81–103.]
- LD50 (rat)N/A
- LD50 (mouse)N/A